Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to us

×

 The MEDCAN Fund 

Investing in the early-stage emerging UK medical & pharmaceutical cannabis sector.

At a glance
  • Current status:                                            Open
  • Fund type:                                               SEIS/EIS
  • Investment goal:                      Capital growth
  • Focus:                    Deep tech & life sciences
  • Target returns:                                                   3x
  • Target holding period:                            8 years
  • Minimum subscription:                        £10,000
Invest here
"The MEDCAN Fund will target qualifying companies that exploit the therapeutic potential of the endocannabinoid system for use in global markets.” - Alexandre Ouimet-Storrs, Óskare Capital UK Ltd.
Óskare Capital UK Ltd has launched the first SEIS and/or EIS fund, investing in innovative companies and teams working on novel therapeutics utilising medical cannabis and other molecules that target an important signalling and regulatory system for maintaining health and fighting disease, the endocannabinoid system.
 
The MEDCAN Fund will target qualifying companies that exploit the therapeutic potential of the endocannabinoid system for use in global markets.
 
The Fund will invest in start-ups across the entire value chain (from molecule to patient) focusing on services and solutions surrounding the endocannabinoid system. It will not invest in growing or producing cannabis, nor will the Fund be involved in businesses or activities related to recreational cannabis.
 
SEIS & EIS tax incentives
The companies the fund invest in are expected to be SEIS-EIS-qualifying, which makes The MEDCAN Fund SEIS-EIS suitable for qualifying clients who would potentially benefit from the following tax reliefs:
  • Up to 30% income tax relief (or 50% for SEIS)
  • Tax-free investment growth
  • Capital gains deferral (or 50% capital gains tax exemption for SEIS)
  • Inheritance tax relief
  • Loss relief
Please note: SEIS-EIS tax reliefs are only made available to investors because of the higher risks associated with investing in early-stage companies. Also, the availability of tax reliefs will depend on the investor's personal circumstances, and tax legislation can change in the future.
Fund team

Examples of the fund team's previous investments

octarine-bio_owler_20200110_172644_original

Octarine harnesses is synthetic biotechnology company with proprietary glycosylation and other functionalisation technologies (platform).

herbolea

Herbolea develops novel biotech processing technologies to manufacture unique high quality products from high therapeutic potential botanicals such as cannabinoids and hops.

Next Slide
prev
next
Want more information?

Book a consultation with one of our team

Explore other investments
Important information

To invest, you must be an eligible investor. To be an eligible investor, you must be qualifying as one or more of the following:

  • You meet the FCA’s definition of a professional investor.

  • You meet the FCA’s definition of a certified high net worth investor.

  • You meet the FCA’s definition of a self-certified sophisticated investor.

  • You meet the FCA’s definition of a self-certified restricted investor.

  • You are a client of an FCA authorised firm that will provide advice on the suitability of the product in question.

 
Risk warning
Important information for private investors – Reliance on the information provided here to engage in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Your attention is drawn to the risk section contained within the Information Memorandum. Investments are typically in unquoted shares in small companies, the value of which can be volatile and are often difficult to sell. Nothing on this website constitutes investment, tax, financial, legal, regulatory, or other advice by Sapphire Capital Partners LLP.
The value of an investment may go down as well as up, and you may not get back the full amount invested, and you may therefore lose some or all of your investment.
If you are unsure of the suitability of any investment for your circumstances, please contact your independent financial advisor or other professional advisor authorised under the Financial Services and Markets Act 2000 (FSMA) who specialises in advising on investments of this type. Tax reliefs depend on individual circumstances. There is no guarantee however that the tax reliefs (such as SEIS and/or EIS reliefs, CGT reliefs or IHT relief) will be available on any investment made or that if it is initially available, it will not be subsequently withdrawn. Any references to tax laws or rates are based on current legislation, all of which are subject to change and are provided as a guide only. Prospective investors are advised to obtain their own investment and taxation advice and should consult their own professional advisors on the implications of investing.
Investments made in investee companies via funds managed by Sapphire Capital Partners LLP may not be covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk
Past performance is not a guide to future returns. CAPITAL AT RISK. 

Get in touch

We are here to help you get started.